News
06-07-2011, 01:30 AM
Celgene International SÃ*rl today announced that results from an investigator-initiated phase II study of ABRAXANE, gemcitabine and bevacizumab as first-line treatment in metastatic breast cancer were presented at the 2011 American Society of Clinical Oncology Annual Meeting in Chicago, IL.
More... (http://www.news-medical.net/news/20110607/Celgene-announces-ABRAXANE-plus-gemcitabine-bevacizumab-phase-II-trial-data-on-breast-cancer.aspx)
More... (http://www.news-medical.net/news/20110607/Celgene-announces-ABRAXANE-plus-gemcitabine-bevacizumab-phase-II-trial-data-on-breast-cancer.aspx)